Annals of Oncology 11:301-306, 2000
© 2000 European Society for Medical Oncology
research-article |
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
1Oncosurgery, Department of Surgery, Hôpital Cantonal Universitaire Geneva
2SIAK coordinating center Bern, Switzerland
3European Institute of Oncology Milan, Italy
4Division of Oncology, Ospedale San Giovanni Bellinzona
5Division of Oncology, Department of Medicine C, Kantonspital St. Gallen
6Institute of Medical Oncology, Inselspital Bern
7Division of Oncology, Department of Medicine Kanlonspital, Basel
8Institute of Oncology and Haematology. Stadtspital Triemli Zürich
9Division of Oncology, Department of Medicine, Hôpital Cantonal Universitaire Geneva
10Division of Oncology, Ospedale Civico Lugano, Switzerland
Correspondence to: A. D. Roth, MD Oncosurgery Geneva University Hospital 24 Micheli-Du-Crest CH-1211 Geneva 14 Switzerland. E-mail: arnaud.roth{at}dim.hcuge.ch
Purpose: A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC).
Patients and methods: Patients with measurable unresectable and/or metastatic gastric carcinoma, performance status 
1, normal hematological, hepatic and renal functions and not pretreated for advanced disease by chemotherapy received up to eight cycles of TC (docetaxel 85 mg/m2 dl, cisplatin 75 mg/m2 dl) q3w. Dose escalation to 100 mg/m2 was performed in five patients and was discontinued for excessive toxicity.
Results: Forty-eight patients were accrued. A median of 5 cycles/patient was given. We observed 2 complete and 25 partial responses for an overall intent to treat response rate of 56% (95% CI: 41%–71%). Twelve patients had stable disease for 
9 weeks (3 cycles). The median time to progression and overall survival were 6.6 and 9 months, respectively. Grade 3 toxicities were neutropenia 81%, anemia 32%, thrombocytopenia 4%, alopecia 36%, fatigue 9%, mucositis 9%, diarrhea 6%, nausea/vomiting 4%, neurologic 2%, and one anaphylaxis precluding treatment administration. We recorded nine episodes of non-fatal febrile neutropenia in eight patients, two of them with docetaxel at 100 mg/m2. There were no direct treatment-related deaths.
Conclusions: TC is active in AGC with a high response rate in a multicentric trial. Despite its hematotoxicity, this regimen is well tolerated and can be recycled as originally planned in 78% of the cases. These results may serve as basis for further developments of docetaxel containing regimens in this disease.
chemotherapy, docetaxel, gastric cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, and D. Wang Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorenzen, M. Hentrich, C. Haberl, V. Heinemann, T. Schuster, T. Seroneit, N. Roethling, C. Peschel, and F. Lordick Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann. Onc., October 1, 2007; 18(10): 1673 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Roth, N. Fazio, R. Stupp, S. Falk, J. Bernhard, P. Saletti, D. Koberle, M. M. Borner, K. Rufibach, R. Maibach, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research J. Clin. Oncol., August 1, 2007; 25(22): 3217 - 3223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Lutz, H. Wilke, D.J. T. Wagener, U. Vanhoefer, K. Jeziorski, S. Hegewisch-Becker, L. Balleisen, E. Joossens, R. L. Jansen, M. Debois, et al. Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 20, 2007; 25(18): 2580 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group J. Clin. Oncol., November 1, 2006; 24(31): 4991 - 4997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, J.-H. Park, S.-J. Bang, D.-H. Kim, H. R. Cho, G. Y. Kim, and Y. J. Min A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU/Platinum Treatment Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Lee, S.-A. Im, T. Yun, E. K. Song, I. i. Na, H. Shin, I. S. Choi, D.-Y. Oh, J. H. Kim, D.-W. Kim, et al. Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 720 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, and M. Lopez Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer Ann. Onc., September 1, 2005; 16(9): 1498 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, M. B. Fodor, S. A. Tjulandin, V. M. Moiseyenko, Y. Chao, S. C. Filho, A. Majlis, S. Assadourian, and E. Van Cutsem Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma J. Clin. Oncol., August 20, 2005; 23(24): 5660 - 5667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Y. Oh, T.-Y. Kim, J. H. Kwon, J.-J. Lee, Y. Joh, D.-W. Kim, T.-Y. Kim, D. S. Heo, Y.-J. Bang, and N. K. Kim Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pasini, G. de Manzoni, C. Pedrazzani, A. Grandinetti, E. Durante, M. Gabbani, A. Tomezzoli, C. Griso, A. Guglielmi, G. Pelosi, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy Ann. Onc., July 1, 2005; 16(7): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Thuss-Patience, A. Kretzschmar, M. Repp, D. Kingreen, D. Hennesser, S. Micheel, D. Pink, C. Scholz, B. Dorken, and P. Reichardt Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study J. Clin. Oncol., January 20, 2005; 23(3): 494 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Van Cutsem The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes Oncologist, June 2, 2004; 9(suppl_2): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth, R. Maibach, N. Fazio, C. Sessa, R. Stupp, R. Morant, R. Herrmann, M. M. Borner, A. Goldhirsch, and F. de Braud 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere(R))-cisplatin in advanced gastric carcinoma: a phase I-II trial Ann. Onc., May 1, 2004; 15(5): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al. Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial J. Clin. Oncol., December 15, 2003; 21(24): 4604 - 4610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodino, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma Ann. Onc., August 1, 2003; 14(8): 1258 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth Chemotherapy in gastric cancer: a never ending saga Ann. Onc., February 1, 2003; 14(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth, A. S. Allal, M.-A. Brundler, R. de Peyer, B. Mermillod, P. Morel, and O. Huber Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study Ann. Onc., January 1, 2003; 14(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Bang, W. K. Kang, Y.-K. Kang, H. C. Kim, C. Jacques, E. Zuber, B. Daglish, Y. Boudraa, W. S. Kim, D. S. Heo, et al. Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 248 - 254. [Abstract] [Full Text] [PDF]
|
|